Research programme: JNK inhibitors - CrystalGenomics
Latest Information Update: 17 Jan 2012
At a glance
- Originator CrystalGenomics
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Inflammation; Neurological disorders